CME Group (CME) Beats Estimates and Sees Shares Climb +6%
Key Takeaways
- Revenue reached a second-quarter record of $1.71 billion, up approximately 1% year-over-year and edging past the Wall Street consensus estimate of roughly $1.68 billion to $1.70 billion.
- Adjusted diluted earnings per share (EPS) came in at $2.99, comfortably ahead of analyst forecasts that ranged from $2.91 to $2.98, while GAAP (Generally Accepted Accounting Principles) EPS was $2.88.
- Market data revenue surged 20% to a record $238 million, marking 33 consecutive quarters of year-over-year growth and helping offset a modest decline in clearing and transaction fee revenue.
- Average daily volume (ADV) of 29.8 million contracts represented the second-highest second quarter in company history, even as it slipped about 1% from the prior-year period.
- CME returned $1.2 billion to shareholders through $468 million in dividends and $695 million in share repurchases, underscoring the company's commitment to capital returns.
- Shares jumped more than 6% following the release, as investors focused on the earnings beat and resilient demand across key product categories.
Putting the Earnings in Context
CME Group entered the second quarter under a cloud of investor anxiety. Since May, when regulators approved cryptocurrency perpetual futures at rival platform Kalshi, CME stock had tumbled roughly 19% on fears that never-expiring contracts could chip away at the company's traditional futures franchise. Against that backdrop, the Q2 2026 report served as a critical test of CME's ability to sustain its institutional dominance and pricing power. The results — featuring record second-quarter revenue, an adjusted EPS beat, and historically strong market data performance — helped calm nerves. With ADV (average daily volume) holding near all-time highs and July volume already tracking 18% above last year, the quarter reinforced the view that CME's diversified product portfolio and deep institutional client base remain powerful competitive moats.
Breaking Down the Reported Results
When CME Group reported second-quarter 2026 revenue of approximately $1.71 billion, it marked a modest increase from the $1.69 billion recorded in Q2 2025 and came in slightly above the consensus analyst estimate. Adjusted diluted EPS landed at $2.99, outperforming the $2.91 to $2.98 range that analysts had projected and edging ahead of the $2.96 posted a year ago. On a GAAP basis, net income was $1.04 billion, or $2.88 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The revenue mix reflected a subtle but important shift. Clearing and transaction fee revenue — the company's traditional core — declined roughly 2.6% year-over-year to $1.35 billion, pressured by softer trading activity in interest rate and energy derivatives. However, market data and information services revenue surged 20% to an all-time quarterly high of $238 million, continuing a remarkable streak of 33 consecutive quarters of year-over-year growth. The total average rate per contract rose to $0.678, a $0.026 sequential increase from Q1 2026, signaling favorable pricing dynamics.
ADV came in at 29.8 million contracts, down about 1% from the prior-year quarter but still the third-highest quarterly ADV on record and the second-best second quarter in CME's history. Equity index ADV jumped 13% year-over-year, agricultural contracts rose 6%, and cryptocurrency volumes also posted gains, while interest rate and energy ADV softened.
Adjusted operating income reached $1.2 billion, translating to a 69.5% adjusted operating margin, while the adjusted net income margin stood at 63.4% — figures that underscore the exchange's exceptional profitability. CME also highlighted a new record in capital efficiencies, saving customers an average of more than $95 billion in margin per day during the quarter.
How the Market Reacted
The market responded enthusiastically to CME Group's second-quarter report, sending shares up more than 6% in the trading session that followed the release. The rally helped recover a portion of the stock's year-to-date losses and signaled that investors were willing to look past the perpetual futures narrative that had weighed on sentiment for weeks. Analysts at Piper Sandler characterized the quarter as "solid," noting that difficult year-over-year volume comparisons made the revenue achievement all the more notable. The combination of an EPS beat, record market data revenue, and strong July volume guidance appeared to re-anchor investor focus on CME's fundamental strengths — its dominant institutional client base, pricing power, and product innovation pipeline — rather than the competitive headlines that had dominated the prior two months.
Exploring Broader Opportunities with AI Tools
Investors looking to identify market opportunities beyond single-stock analysis may find value in Tickeron's AI Screener. The AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that allows traders and investors to filter the market using a wide range of customizable criteria, including technical patterns, fundamental metrics, volatility profiles, and AI-driven signals. Users can scan thousands of securities by industry, market capitalization, technical indicators, price patterns, and performance metrics, helping to surface trade ideas, trending stocks, breakout candidates, and emerging market themes more efficiently than traditional manual screening. For those monitoring earnings seasons and sector rotations, the AI Screener offers a practical way to stay ahead of shifting market dynamics. I’ve found it helpful for quickly comparing CME against peers during volatile periods like this one.
What to Watch Going Forward
Looking ahead, several factors will shape CME Group's trajectory through the second half of 2026 and into 2027. The most immediate positive signal came from management's disclosure that July-to-date volumes are running 18% above the prior-year period, suggesting that the modest ADV softness observed in Q2 may prove temporary.
Product innovation remains a central theme. CME is moving forward with several initiatives, including the launch of single-stock futures and 24/7 trading of crypto futures, as well as the planned introduction of TreasuryLink — a platform designed to connect U.S. Treasury futures with cash Treasury liquidity pools. These offerings could drive incremental volume growth and diversify the revenue base further, though regulatory approvals and market adoption will dictate their impact.
The competitive landscape, particularly around perpetual futures, will continue to draw scrutiny. CME has taken legal action against the CFTC (Commodity Futures Trading Commission) over what it describes as "competitive injury" from the approval of perpetual futures at rival venues. The resolution of this dispute — whether through the courts, regulatory adjustments, or market-driven outcomes — has the potential to influence the long-term competitive dynamics of the derivatives industry.
Leadership transition is another factor to monitor. In June, CME announced that CEO Terry Duffy will transition to the role of Executive Chairman in March 2027, with President and CFO Lynne Fitzpatrick set to take the helm. The succession plan introduces a period of executive-level change, though the early announcement and internal promotion suggest a deliberate and orderly handover.
Finally, capital allocation remains a bright spot. With $2.3 billion in cash on the balance sheet and a demonstrated willingness to return capital aggressively — $1.2 billion in Q2 alone through dividends and buybacks — CME continues to reward shareholders while maintaining the flexibility to invest in growth. Investors will watch whether the pace of buybacks continues and whether market data revenue can sustain its multi-year growth streak as the macroeconomic backdrop evolves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CME in upward trend: 10-day moving average moved above 50-day moving average on October 14, 2026
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 62 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 26 of 48 cases over the following month. The odds of a continued upward trend are 54%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 171 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CME entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 31 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.569) is normal, around the industry mean (-5.093). P/E Ratio (22.327) is within average values for comparable stocks, (25.252). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). CME has a moderately high Dividend Yield (0.043) as compared to the industry average of (0.018). CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
Advertisement